Best Health CareStocks — Ranked by 5 Models
Pharmaceuticals, biotechnology, medical devices, health services, and managed care.
Data as of
168 companies
Health Care Companies (168)
All Health Care Companies
Sign in to see all Health Care stocks ranked by score
Start Free →How the five models treat Health Care
| Profile | Models | Fair value | Q / V / M / T |
|---|---|---|---|
| General |
| Two-stage owner-earnings DCF (Damodaran industry cost of equity) | 40% / 10% / 35% / 15% |
A model that does not apply is left out of the company's axis, never scored as zero. Full definitions on the methodology page.
Investing in Health Care Stocks
No other sector has such a sharp divide between what the models can see and what actually drives returns. A pharma company might have pristine financials today, but if its lead drug loses patent exclusivity next year, those numbers will not last. Conversely, a biotech burning cash on Phase III trials might be sitting on a blockbuster. Our models are honest about this limitation — they evaluate realized financial data from SEC filings, not pipelines, patents or trial results.
Health care companies use the general profile. Graham's criteria reward long, unbroken records of earnings and dividends, which established pharmaceutical and managed-care companies tend to have and pre-revenue biotechs cannot. Piotroski checks whether the latest year improved on the last: profitability, cash flow above earnings, leverage, margins, asset turnover. Buffett looks for returns on equity and tangible capital that held up for a decade and margins that stayed stable — the financial trace of a durable business, whatever its source.
Demographics are the tailwind that makes health care a perennial favorite for long-term portfolios. An aging global population drives sustained demand for medical services, drugs, and devices regardless of economic conditions. Managed care companies capture this through premium growth. Medical device makers benefit from procedure volume increases. Large-cap pharma names provide defensive ballast during market selloffs.
Don't dismiss low-scoring biotechs automatically: a low score means the company has not yet shown the financial record the models measure, not that the investment thesis is wrong. And a high score on a drug maker says nothing about its patent cliff — check that yourself.
Health Care Stocks — Frequently Asked Questions
How does AlphaStocks account for drug pipeline risk in health care scores?
It does not. The models use only realized financial data from SEC filings — earnings, cash flow, balance sheets, dividends — not pipelines, patents or trial outcomes. That favors established companies with proven revenue and says nothing about a coming patent expiry.
Which health care stocks are best for defensive portfolios?
The models cannot answer "defensive" directly, but long unbroken earnings and dividend records (Graham), returns that held up for a decade (Buffett) and an improving latest year (Piotroski) are the financial traits defensive holdings usually share. Check the model cards on each stock page.
Why do some biotech stocks score low on AlphaStocks?
Pre-revenue or early-stage biotech companies often score low, or get "insufficient data", because the models rely on actual financial metrics like profitability, cash flow, and earnings records. A low score does not mean the stock is a bad investment — it means the company has not yet shown the financial record the models measure.